Koppert, the global leader in biological crop protection and pollination, and Amoéba, an industrial greentech specialised in natural microbiological solutions based on the patented use of amoebae, are pleased to announce the signing of a significant commercial agreement on Tuesday, June 3. This agreement focuses on the innovative biofungicide solution created by Amoéba and follows the recent approval of Amoéba’s biocontrol active substance by the European Union Member States. The launch is expected early 2026.
The innovative biofungicide solution is based on the lysate of the amoeba Willaertia magna C2c Maky. It is an environmentally friendly biofungicide, that protects crops against a broad range of diseases. The agreement grants Koppert exclusive distribution rights for a period of five years for this biocontrol product, targeting vines and vegetable crops grown both in greenhouses and open fields across 18 European countries (including France, the Netherlands, Germany, Italy), as well as in the United States. The launch is expected in early 2026, and Koppert will distribute this biofungicide under its own brand name. In addition, Koppert and Amoéba will collaborate for the potential launch in Brazil.
Koppert and Amoéba will evaluate the future production organization based on operational feedback and projected commercial scale-up.
Martin Koppert, Chief Business Officer of Koppert, says: “This agreement marks a significant step forward in expanding our portfolio of innovative biological solutions. This new biofungicide solution is an exciting addition that aligns perfectly with our mission to support growers with sustainable and effective crop protection tools. We look forward to a successful collaboration with Amoéba, bringing the benefits of this breakthrough technology to farmers across the world.”
Jean-François Doucet, Chief Executive Officer of Amoéba, says: “The signing of this commercial agreement with the world leader in biocontrol is a key moment in the history of Amoéba. The discussions over the last few months have been very fruitful and we are delighted to have reached a mutually beneficial agreement. This agreement once again demonstrates the potential and promising prospects of our biofungicide solution. We now look forward to working together.
